Regeneron Pharmaceuticals competitors, on the record

Who Regeneron Pharmaceuticals names

In its own words

1. AstraZeneca, Bristol-Myers Squibb, Merck, Roche, Sun Pharma

   Word for word“There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025

2. Genentech/Roche

   Word for word“Ophthalmologists are also using off-label, third-party repackaged versions of Genentech/Roche's approved VEGF antagonist, bevacizumab, for the treatment of certain of EYLEA HD's and EYLEA's respective indications, and we are aware of another company developing an ophthalmic formulation of such product that has been approved in the EU.” 10-K for 2025

Who names Regeneron Pharmaceuticals

Companies whose own annual reports name Regeneron Pharmaceuticals as a competitor.

1. Amgen names it as “Regeneron Pharmaceuticals, Inc.” · 2025

   Word for word“Product Territory Competitor-marketed product Competitors Prolia U.S., Europe & Asia Pacific Bisphosphonates, including generics Various U.S., Europe & Asia Pacific Denosumab biosimilars Various Repatha U.S., Europe & Asia Pacific LEQVIO ® Novartis AG U.S., Europe & Asia Pacific PRALUENT ® Regeneron Pharmaceuticals, Inc.” 10-K for 2025

Read from Regeneron Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-04. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.